SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

(Mark one)

[X]  Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange
     Act of 1934.


For the period ended March 31, 1999.

[_]  Transition Report Pursuant to Section 13 or 15(d) of the Securities
     Exchange Act of 1934.

For the transition period from__ to__.



Commission File Number: 0-16128

                              TUTOGEN MEDICAL, INC.
             (Exact name of registrant as specified in its charter)

Florida                                                               59-3100165
(State or other Jurisdiction of                                 (I.R.S. Employer
Incorporation or Organization)                               Identification No.)


1719 Route 10, Suite 314, Parsippany, New Jersey                           07054
(Address of Principal Executive Offices)                              (Zip Code)


Registrant's telephone number, including area code:               (973) 359-8444


Securities registered pursuant to Section 12(b) of the Act:                 None


Securities registered pursuant to Section 12(g) of the Act:


Common Stock, par value $.01
     (Title of Class)                (Name of Each Exchange on Which Registered)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding  months ( or for such  shorter  period  that the  Registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days. Yes X No_.

As of April 30,  1999  there  were  outstanding  10,715,714  shares  of  Tutogen
Medical, Inc. Common Stock, par value $0.01.



<PAGE>




                     TUTOGEN MEDICAL, INC. AND SUBSIDIARIES

                                      INDEX



PART I.              Financial Information.

           ITEM 1.   Financial Statements.

                     Consolidated Balance Sheets - March 31,
                     1999 and 1 September 30, 1998.                           1

                     Consolidated Statements of Operations for
                     the 2 three and six months ended March
                     31, 1999 and 1998.                                       2

                     Consolidated Statements of Cash Flows for
                     the six 3 months ended March 31, 1999 and
                     1998.                                                    3

                     Notes to Consolidated Financial Statements.              4

           ITEM 2.   Management's Discussion and Analysis of Financial        6
                     Condition and Results of Operations.

PART II.             Other Information.

           ITEM 4.   Submission of Matters to a Vote of Security-             9
                     Holders.

           ITEM 6.   Exhibits and Reports on Form 8-K                         9

SIGNATURES                                                                   10


<PAGE>


                PART I. FINANCIAL INFORMATION

Item 1.  Financial Statements.



                     TUTOGEN MEDICAL, INC. AND SUBSIDIARIES
                           CONSOLIDATED BALANCE SHEETS
                                 (in thousands)


                                                     (unaudited)     (audited)
                                                       March 31,   September 30,
                                                        1999          1998
                                                       -------       -------

ASSETS

Current Assets
    Cash and cash equivalents                          $   287       $   357
    Accounts receivable                                  1,508         1,685
    Inventories                                          4,321         4,435
    Other current assets                                   393           173
                                                       -------       -------
                                                         6,509         6,650

Property, plant and equipment, net                       2,712         2,995

Intangible and other assets, net                           382           596
                                                       -------       -------
TOTAL ASSETS                                           $ 9,603       $10,241
                                                       =======       =======


LIABILITIES AND SHAREHOLDERS' EQUITY

Current Liabilities
    Accounts payable                                   $   711       $ 1,010
    Accrued interest                                       118           189
    Other accrued expenses                               1,021           953
    Revolving credit arrangements                          644           895
    Current portion of long-term debt                      120           162
                                                       -------       -------
                                                         2,614         3,209

Other Liabilities
    Long-term debt                                       1,477         3,644
    Other long-term obligations                             15            17

Shareholders' Equity                                     5,497         3,371
                                                       -------       -------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY             $ 9,603       $10,241
                                                       =======       =======


See accompanying Notes to Consolidated Financial Statements.



                                       1
<PAGE>


                     TUTOGEN MEDICAL, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                      (in thousands except per share data)


<TABLE>
<CAPTION>
                                         Three Months Ended March 31,     Six Months Ended March 31,
                                         ----------------------------    ----------------------------
                                             1999            1998            1999            1998
                                         ------------    ------------    ------------    ------------
<S>                                      <C>             <C>             <C>             <C>         
OPERATING REVENUES
          Revenue                        $      2,769    $      1,968    $      5,281    $      3,916
          Cost of revenue                       1,640           1,095           3,098           2,261
                                         ------------    ------------    ------------    ------------

             Gross margin                       1,129             873           2,183           1,655


OPERATING EXPENSES
         General and administrative               600             474           1,055             863
         Distribution and marketing               590             371           1,006             665
         Research and development                 124              58             206             124
         Depreciation and amortization            124             173             248             356
                                         ------------    ------------    ------------    ------------
                                                1,438           1,076           2,515           2,008

Operating loss                                   (309)           (203)           (332)           (353)


License fee                                        --            (200)             --            (200)
Other (income)                                   (138)            (41)           (151)            (55)
Interest expense                                   47              83             138             180
                                         ------------    ------------    ------------    ------------
                                                  (91)           (158)            (13)            (75)

Net loss before income taxes                     (218)            (45)           (319)           (278)

Income taxes                                       --              --              --              --
                                         ------------    ------------    ------------    ------------

NET LOSS                                 $       (218)   $        (45)   $       (319)   $       (278)
                                         ============    ============    ============    ============

Average common shares outstanding          10,625,520       5,313,832       7,972,909       4,867,482
                                         ============    ============    ============    ============

Net loss per share                       $      (0.02)   $      (0.01)   $      (0.04)   $      (0.06)
                                         ============    ============    ============    ============
</TABLE>


See accompanying Notes to Consolidated Financial Statements



                                       2
<PAGE>

                     TUTOGEN MEDICAL, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENT OF CASH FLOWS
                                 (in thousands)


                                                              Six Months Ended
                                                                  March 31,
                                                             ------------------
                                                              1999       1998
                                                             -------    -------

Cash flows from operating activities
Net loss                                                     $  (319)   $  (278)
Adjustments to reconcile net loss to net cash
  used in operating activities:
  Depreciation and amortization                                  403        637
  Increase (decrease) in cash resulting from changes in:
     Accounts receivable                                         177        106
     Inventories                                                 114       (821)
     Prepaid expenses and other current assets                  (220)       (97)
     Accounts payable and accrued liabilities                    (20)       (40)
                                                             -------    -------
        Net cash used in operating activities                    135       (493)


Cash flows from investing activities
   Purchase of property, plant and equipment                    (152)       (93)
                                                             -------    -------
      Net cash provided by (used in) investing activities       (152)       (93)

Cash flows from financing activities
    Issuance of stock                                            408      4,185
    Proceeds from long-term borrowings                            --        500
    Repayment of short-term borrowings                          (200)    (3,886)
    Repayment of long-term debt                                  (29)      (119)
                                                             -------    -------
         Net cash provided by financing activities               179        680


Effect of exchange rate changes on cash                         (232)      (115)

Net decrease in cash and cash equivalents                        (70)       (21)

Cash and cash equivalents at beginning of period                 357        777
                                                             -------    -------

Cash and cash equivalents at end of period                   $   287    $   756
                                                             =======    =======


--------------------------------------------------------------------------------


Supplemental cash flow disclosures
      Interest paid                                          $    58    $   180
                                                             =======    =======

Schedule of noncash financing activities:
      Issuance of common stock in exchange for
          convertible long-term debt and accrued interest    $ 2,162    $    --
      Issuance of common stock for interest                      376         --
                                                             -------    -------
                                                             $ 2,538    $    --
                                                             =======    =======


See accompanying Notes to Consolidated Financial Statements

                                       3
<PAGE>


                     TUTOGEN MEDICAL, INC. AND SUBSIDIARIES
              NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
                                 March 31, 1998
                        (in thousands, except share data)



(1)  OPERATIONS AND ORGANIZATION

     Tutogen  Medical,  Inc.  along  with its  consolidated  subsidiaries  ("the
     Company")  processes,  manufactures  and  distributes  worldwide  specialty
     surgical  products  and  provides  tissue  processing  services  for neuro,
     orthopedic,    cardiovascular,    reconstructive   and   general   surgical
     applications.  The Company's core business is processing human donor tissue
     ("allografts") utilizing its patented Tutoplast(R) process for distribution
     to hospitals and surgeons.

(2)  SIGNIFICANT ACCOUNTING POLICIES

     The accompanying unaudited consolidated financial statements of the Company
     and the unaudited results of operations and cash flows for the three months
     ended  March 31,  1999 and 1998  have  been  prepared  in  conformity  with
     generally accepted accounting  principles for interim financial  reporting.
     Accordingly,  they do not include all of the information and notes required
     by  generally  accepted   accounting   principles  for  complete  financial
     statements.  In the opinion of  management,  all  adjustments  necessary in
     order to make the  financial  statements  not  misleading  have been  made.
     Operating results for the three and six months ended March 31, 1999 are not
     necessarily  indicative of the results which may be expected for the fiscal
     year ending September 30, 1999. The interim financial  statements should be
     read in conjunction with the audited  consolidated  financial statements of
     the Company for the year ended September 30, 1998.

(3)  INVENTORIES

     Major classes of inventory at March 31, 1999 and September 30, 1998 were as
     follows:

                                                   March 31,    September 30,
                                                     1999           1998
                                                    -------        -------

     Raw materials                                  $ 1,468        $ 1,473
     Work in process                                  2,284          2,729
     Finished goods                                   1,301          1,249

     Less reserves for obsolescence                    (732)        (1,016)
                                                    -------        -------

                                                    $ 4,321        $ 4,435
                                                    -------        -------



                                       4
<PAGE>


(4)  SHAREHOLDERS' EQUITY

     On January 28, 1999, one of the Company's institutional investors converted
     its Convertible Debenture and accrued interest and expenses  (approximately
     $2,162)  into  4,600,507   shares  of  the  Company's   common  stock.   In
     consideration  of the  agreement  to  convert,  the  Company  issued to the
     investor  149,334 common shares as prepayment for one years interest on the
     Debenture  and agreed to amend its  outstanding  Stock  Purchase  Warrants,
     totaling 1,353,957,  by reducing the exercise price from $2.50 per share to
     $1.25 per share if such  warrants  are  exercised  prior to June 30,  2000,
     after which date such warrants shall revert to their initial terms.

     During the quarter ended March 31, 1999, this same institutional  investor,
     a Director of the Company and a private investor  purchased  300,000 Units,
     100,000 Units and 7,500 Units,  respectively,  at $1.00 per Unit, each Unit
     consisting of one common share of the Company and one Common Stock Purchase
     Warrant, expiring March 31, 2000, at an exercise price of $1.50 per share.









                                       5
<PAGE>



       ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
                           AND RESULTS OF OPERATIONS
                                 (in thousands)

Results of Operations

Net Loss

Net loss for the three  months  ended March 31, 1999  totaled  $218 or $0.02 per
share as  compared to a net loss of $45 or $0.01 per share for the same period a
year ago. The net loss for the six months ended March 31, 1998 was $319 or $0.04
per share as compared  to a net loss of $278 or $0.06 per share.  The net losses
for the three and six months ended March 31, 1998 were reduced by the  inclusion
of an up-front license fee of $200.

Revenue and Cost of Revenue

Revenue for the three months ended March 31, 1999  increased  41% to $2,769 from
$1,968 for the  comparable  period.  The US operation  has more than doubled its
revenue to $1,111  from $484 for the same  period  last  year.  This is a direct
result of its strategic  alliances with the Mentor Corporation and IOP, Inc. and
a 78% increase in revenues on the Company's  core  neurosurgical  business.  The
International  operation had a revenue increase of 10% from the same period last
year.  The revenue for the six months  ended  March 31,  1999  increased  35% to
$5,281 from $3,916 for the comparable  period. The revenues for the US operation
were $2,018 or a 135%  increase  from $859 for the same  period  last year.  The
revenues for the  International  operation  increased by 9% from the same period
last year.

Gross  margins for the three months  ended March 31, 1999  decreased to 41% from
44% for the  comparable  period last year.  The gross margins for the six months
ended March 31, 1999  decreased to 41% from 42% for the  comparable  period last
year. The decrease was primarily  attributable to an unfavorable mix of products
sold at both the US and International operations.

General and Administrative

General and administrative  expenses increased 27% and 22% for the three and six
months ending March 31, 1999,  respectively,  from the  comparable  periods last
year.  The increase was due  primarily to an increase in legal,  consulting  and
travelling expenses.

Distribution and Marketing

Distribution and marketing  expenses increased 59% and 51% for the three and six
months ending March 31, 1999,  respectively,  from the  comparable  periods last
year. The increase was primarily  associated with the building of a direct sales
force in Germany and the costs associated with the introduction of a new product
line, Tutoplast(R) bovine pericardium.

Research and Development

Research and development  expenses  increased 114% and 66% for the three and six
months ending March 31, 1999,  respectively,  from the  comparable  periods last
year.  The increase was due to the  expansion of the R & D effort in Germany and
travelling and personnel costs to expand the tissue recovery sites in Europe.



                                       6
<PAGE>

Depreciation and Amortization

Depreciation and amortization decreased 28% and 30% for the three and six months
ending March 31, 1999, respectively,  from the comparable periods last year. The
reduction in  depreciation  and  amortization  was  attributed to an increase in
fully depreciated property, plant and equipment.

Interest Expense

Interest  expense declined 43% and 23% for the three and six months ending March
31, 1999,  respectively,  from the comparable  periods last year. Lower interest
was the direct  result of capital  restructurings  completed  during the quarter
ending  December 31, 1997 and the recent  conversion of $2,074 of long-term debt
to common stock at the end of January of 1999.

Liquidity and Capital Resources

At March 31, 1999 and  September  30,  1998 the  Company had working  capital of
$3,895  and  $3,441,  respectively.   The  Company  maintains  revolving  credit
facilities totaling DM 2,360 (approximately  $1,400) with three German banks. At
March 31, 1999 the Company had borrowed $644 against these lines.

In the past the Company has relied upon its available  working capital lines and
institutional  investors to fund operational cash flow, when needed.  During the
quarter ended March 31, 1999, one of the Company's  institutional  investors,  a
Director of the Company and a private investor purchased 300,000 Units,  100,000
Units and 7,500 Units, respectively,  at $1.00 per Unit, each Unit consisting of
one common share of the Company and one Common Stock Purchase Warrant,  expiring
March 31,  2000,  at an  exercise  price of $1.50 per share.  In  addition,  the
Company is continuing to seek other investors to infuse additional  capital into
the Company.  While  management  believes that it will be successful in securing
new funding,  there can be no assurances  that it will be able to do so. Lack of
new funding  along with the  inability  to increase  processing  revenues  could
result in a curtailment of operations in the future.

The Company's  ability to generate  positive  operational cash flow is dependent
upon increasing processing revenues through increased recoveries by tissue banks
in the U.S. and Europe,  and the development of additional  markets and surgical
applications  worldwide.  While the Company  believes  that it continues to make
progress  in  both  these  areas,  there  can  be no  assurances  that  changing
governmental  regulations  will not have a material adverse effect on results of
operations and cash flow.

Government Regulation

It has  previously  been  reported  in an SEC  filing  that  the  Food  and Drug
Administration ("FDA") has raised a concern about the potential for transmission
of  Creutzfeldt-Jacob  Disease ("CJD") from one lot of  Tutoplast(R)  Dura Mater
processed by the Company in Germany  before April 1994.  The FDA and the Centers
for Disease  Control and  Prevention  ("CDC") have  investigated  an incident in
which a patient who received a  Tutoplast(R)  Dura Mater  transplant in 1992 was
diagnosed with CJD in 1998. Although there have been no other reports of disease
transmission  associated with over 500,000  Tutoplast(R) Dura Mater transplants,
based on the investigation conducted by FDA and CDC, the Company cannot rule out
with absolute  certainty at this time that Tutoplast(R) Dura Mater may have been
the possible cause of CJD in this incident.




                                       7
<PAGE>

Consequently, the Company has voluntarily recalled from the market all sizes and
lots of Tutoplast(R)  Dura Mater processed in Germany before 1994 under the same
conditions as the lot that is the subject of FDA's  concern.  All sizes and lots
of Tutoplast(R) Dura Mater bearing an expiration date after April 1999 that were
processed by the  Company's  US  operation  at its facility in Alachua,  Florida
since  April  1994,  under  conditions  that  meet  current  United  States  and
International standards and regulatory requirements, are not involved. There has
been no recall requested by the German health  authorities.  However,  they have
raised the regulatory  requirements on dura mater.  The Company will comply with
these new requirements.

While  there have been no returns of product in the U.S.,  it will take  several
weeks to comply with the new requirements in Germany.  Meanwhile, the Company is
offering  alternative  tissues such as fascia lata and bovine pericardium to the
market.  Nevertheless,  the  impact of the delay in  supplies  caused by the new
requirements on dura mater is estimated to be a loss of $350,000 in revenues and
reduced profits of $210,000 for the fiscal year.

Year 2000 Compliance

Management  has recently  become aware that one of the operating  systems in the
International operations is not currently Year 2000 compliant. The International
operation is currently implementing a new operating system, which will encompass
the  necessary  amendments  for the system to become  Year 2000  compliant.  The
implementation  is expected to be completed by September  1999. The costs of the
Year  2000  upgrade  are  included  in  the  overall  implementation  cost,  and
therefore, are not separately identifiable.






                                       8
<PAGE>


PART II. OTHER INFORMATION


Item 4. Submission of Matters to a Vote of Security-Holders

     An  annual  Meeting  of  Stockholders  was  held  on  April  8,  1999.  All
     management's  nominees for director,  as listed in the Proxy  Statement for
     the Annual Meeting, were elected.  Listed below are the matters voted on by
     stockholders and the number of votes cast at the Annual Meeting:


(a)  Election of seven members of the Board of Directors.

                                                               Broker
                                      Voted       Votes        Non-Votes
Name                    Voted For     Against     Withheld     and Abstentions
----                    ---------     -------     --------     ---------------

G. Russell Cleveland    9,034,822     0            4,617       0
Charles C. Dragone      9,035,122     0            4,317       0
J. Harold Helderman     9,035,122     0            4,217       0
Manfred Kruger          9,030,122     0            9,317       0
Karl H. Meister         9,030,222     0            9,217       0
Thomas W. Pauken        9,035,222     0            4,217       0
Elroy G. Roelke         9,035,122     0            4,317       0



(b)  Ratification   of  the   appointment  of  Deloitte  and  Touche  L.L.P.  as
     independent  auditors of the  Company for the fiscal year ending  September
     30, 1999.


                           Voted For:                         9,035,991
                           Voted Against:                         1,795
                           Voted Abstained:                       1,653
                           Broker Non-Votes                           0




Item 6. Exhibits and Reports on Form 8-K.

Exhibits
--------

 No. 27            Financial Data Schedule



No reports on Form 8-K were filed by the Company  during the quarter ended March
31, 1999.


                                       9
<PAGE>

SIGNATURES

Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
Pursuant to the  requirements  of the  Securities  and Exchange Act of 1934, the
undersigned, thereunto duly authorized.

                                    Tutogen Medical, Inc.




Date:  May 7, 1999                  /s/ Karl H. Meister
                                    -------------------
                                    President and Chief Executive Officer




Date:  May 7, 1999                  /s/ George Lombardi    
                                    -----------------------
                                    Chief Financial Officer
                                    (Principal Financial and Accounting Officer)





                                       10